Introduction
Tissue factor (TF) was originally known for its role in blood coagulation; upon binding of TF to the zymogen FVII, the FVIIa:TF complex induces the formation of a blood clot via the sequential formation of FXa, thrombin and fibrin (1). Research, however, performed in the last decade demonstrated an important role for TF in inflammation, sepsis, angiogcnesis and metastasis (2-4). Furthermore, direct correlations between TF expression and advanced stages of malignancy have been observed in breast cancer, colorectal cancer, pancreatic cancer and glioma, suggesting a possible role for TF in tumor development (5) (6) (7) (8) . It is now believed that FVIIa-induced intracellular signaling on TF expressing cells is important for processes such as angiogcnesis and inflammation. Nevertheless, coagulation factor-evoked signal transduction in general and FVIIa-dcpendent signaling in particular remain among the least understood signaling cascades in physiology. It has become clear, however, that FVlla:TF interaction results in cytoskeletal rearrangements and in gene transcription (9-11). The latter may lead to synthesis of proteins, such as IL-8, which are potent inducers of inflammation and angiogenesis (12).
One of the major pathways triggered by the FVIIa:TF complex is the Mitogen-Activated Protein (MAP) Kinase pathway. The MAP kinase family consists of several members, among which p42/p44 MAP kinase, p38 MAP kinase and c-Jun-N-terminal kinase are the most prominent. Although not all members of MAP kinase family arc activated in the various cells that react to FVIIa-stimulation, p42/p44 MAP kinase activation is consistently observed in all TF-expressing cell types investigated (9, 13, 14) . Furthermore it has been shown that this p42/p44 MAP kinase activation mediates important downstream effects, like e.g. p90 Rsk stimulation (15). Strikingly, the nature of the upstream signal transducers that mediate p42/p44 MAP kinase activation remains unclear; some researchers have suggested the involvement of so-called protcase-activated receptors (PARs) (16). These G-protein-couplcd receptors which are activated upon proteolytic cleavage of the N-terminal part, consist of four known members; PAR-1 is activated by thrombin and FXa, whereas PAR-3 and -4 are exclusively activated by thrombin. Finally, PAR-2 is activated by both FXa and FVIIa. The involvement of PARs as receptors in FVIIa-induced signaling, however, has been questioned by other groups that have found no evidence for involvement of any of the known PARs in BHK cells stably transfected with TF (17).
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Ras is a 21 kDa small G-protcin that is mutated in 30% of all human tumors, and therefore it is believed to play a key role in cell transformation. p21Ras activation will typically result in MAP kinase activation, but is not strictly essential for this process. The involvement of p21Ras in FVIIa-induced MAP kinase activation has not been addressed as yet. This prompted us to investigate the potential of FVIIa to induce p21 Ras activation in two different cell types. We show a transient activation of p21Ras upon FVIIa-stimulation in BHK cells and in spontaneously immortalized keratinocytes (HaCaT). Interestingly, regulation of p21Ras activation differs between these two cell types; whereas p21Ras activation in HaCaT is dependent on Src-like kinase activity, p21Ras activation in BHK cells is dependent on Protein Kinase C (PKC) activation and another yet to be identified signal transducer. We hypothesize that this differential activation of p21Ras may reflect the involvement of different receptors in the cell types investigated.
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Experimental procedures
Reagents-All phosphospecific antibodies were purchased from Cell Signaling Technologies (Beverly, MA), whereas antibodies against total MAP kinase were from Santa Cruz. The Ras activation kit and the antibody directed against p21Ras was from Upstate Biotech Inc.
(Waltham, MA) and the monoclonal HA antibody was from Sigma (St. Louis, MO, USA).
PP1 and GF-109203X were from Biomol and LY294002 was from Alexis (Montreal, Canada) Ras activation assay-The p21 Ras activation assay was performed according to the protocol supplied by the manufacturer. Briefly, cells, grown in 10 mm culture plates were stimulated with FVIla and subsequently washed with cold PBS. The cells were lysed in 1 ml lysisbuffer (25 mM HEPES (pH 7.5), 150 mM NaCl, 1% NP-40, 10 mM MgC12, ImM EDTA, 10% glycerol) and samples were taken for analysis of MAP kinase phosphorylation. Subsequently, cell debris was spun down at 14,000 rpm for 2 min and the supernatant was incubated with 10 ml 50% agarose beads, coated with the Raf GTP-ras-binding domain for 30 min at 4°C.
Subsequently, the beads were washed three times with lysis buffer and the beads were resuspended in denaturing sample buffer (125 mM Tris/HCl, pH 6.8; 4% SDS; 2% bmercaptoethanol; 20% glycerol, 1 mg/ml bromophenol blue).
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Transfection and immunoprecipitation-Cells, seeded in 6-well plates, were transfected with Effectene, according to the manufacturer's protocol. Per condition. 0.2 mg pcDNA3-HA-ERK1 (HA-p44) with either 0.2 mg vector pRSV-RasN17 (a gift from Dr. Paul Coffer, Department of Pulmonary Diseases. Utrecht University) or empty vector was co-transfected.
After overnight incubation, the cells were serum starved for 16 h. and subsequently stimulated for the times indicated. The cells were lysed in 0.5 ml lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA. 1 mM EGTA. 1% Triton, 2.5 mM sodium pyrophosphate. 1 mM beta-glycerophosphate, 1 mM NasVO.». 1 ug/ml leupeptin) and were collected by scraping.
Subsequently, the lysate was centrifuged at 14.000 rpm for 2 min, and the supernatant was precleared with 20 ml 50% protein A-sepharose for lh. The lysate was then incubated overnight with 1 mg HA antibody. The immuno complex was precipitated with 20 ml 50%
protein A-sepharose for lh. The beads were washed three times with lysis buffer and were subsequently resuspended in 40 ml denaturing sample buffer.
Western Blotting-The samples were incubated for 5 min at 95°C, after which 30 ml of the lysates were loaded onto SDS-PAGE and subsequently transferred to a PVDF membrane. The membranes were blocked with Tris-buffered saline (TBS) supplemented with 0.1% tween-20
(wash buffer) and 2% low-fat milk powder, and incubated with primary antibodies over night at 4°C, diluted 1:1000 in wash buffer. Subsequently, the membranes were incubated with a horseradish peroxidase-conjugated secondary antibody in wash buffer, containing 2% low-fat milk powder. The bands were visualized, using Lumilight plus® ECL substrate from Roche and a chemiluminesccnce detector with a cooled CCD-camcra (Gencgnome) from Syngene.
Antibody bands were quantified using Genetools from Syngene. within 5 min. As a control, also total p21 Ras levels were analyzed and these were not affected by FVIIa stimulation (Fig I A) . The transient p21Ras activation correlated with the onset of p42/p44 MAP kinase activation, which was measured in the same samples using a phosphospecific antibody and Western Blotting (Fig IB) . We also investigated FVIIa-induccd -61- (Fig 2A) or HaCaT cells (Fig 2B) , whereas TAP and hirudin potently inhibited FXa-and thrombin-induced MAP kinase activation, respectively ( Fig 2C) . Therefore, FVIIa-dependent FXa and thrombin generation do not contribute to FVIIa-induced p21Ras activation and p42/p44 MAP kinase stimulation in our experimental set up.
Results
FVIIa induces p21Ras activation in BHK
Ras activity is essential for FVIIa-induced MAP kinase activation-To address the issue as
to whether activation of the MAP kinase pathway is actually dependent on p21Ras or whether this p21Ras activation is a coincidental phenomenon, we co-transfected cells with HA-tagged p44 MAP kinase and p21RasN17, an inactive p21Ras mutant. After stimulation, HA-p44 was immunoprecipitated, using a HA-antibody, and HA-p44 was analyzed for phosphorylation status on Western Blot. Both in BHK TF (Fig. 3A) and HaCaT cells ( -64- Again, phosphorylation of both Src-like kinases and PKC-like kinases was observed in this cell type (Fig 6A) . However, whereas PP1-treatment abolishes FVIIa-induced p21Ras and MAP kinase activation in HaCaT, PPI did not effect either Ras activation (Fig 6B) or p42/p44 MAP kinase stimulation (Fig 7A) in BHK rF cells. In addition, preincubation with the PI3-kinase inhibitor LY294002 did not have any effect, but pretreatment with the PKC-inhibitor GF-109203X, strongly delayed FVIIa-dependent p21 Ras activation (Fig 6A,B) and abolished early p42/p44 MAP kinase activation in BHK TF cells (Fig 7B) . These data suggest that PKC activation is important in p21Ras activation in BHK TF cells but not in HaCaT cells. In addition, since PKC inhibition did not completely inhibit p21Ras-MAP kinase signaling, other signal transducers are likely to play a role in p21Ras-MAP kinase signaling in BHK TF cells. Thus, although the activation p21Ras seems to be a general feature of FVIIa-induced signaling, the molecular mechanisms by which this p21Ras activation is achieved shows considerable cell type specificity.
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